<DOC>
	<DOCNO>NCT01813487</DOCNO>
	<brief_summary>The purpose study examine immunogenicity efficacy HBsAg Vaccine combination Entecavir patient treat HB110E HBV DNA vaccine .</brief_summary>
	<brief_title>Study Immunogenicity Efficacy HBsAg Vaccine Combination With Standard Antiviral Therapy With HB110E</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>subject treat HB110E 2mg 4mg within 6 month prior screen . positive HBsAg screen serum HBV DNA level 300copies/mL screening ALT level within 2 x ULN screen voluntarily provide informed consent participation study within 30 day screen subject severe allergic reaction severe adverse event HBsAg vaccine , suitable HBsAg vaccine . condition consider inappropriate study investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>